alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

No. 15-541V Filed: September 10, 2015 Unpublished

* * * * * * * * * * * * * * * * * * * * * * * * * * * * WINIFRED CAMPBELL, *

* Petitioner, * Ruling on Entitlement; Concession; * Influenza (“Flu”) Vaccine; Shoulder * Injury Related to Vaccine Administration SECRETARY OF HEALTH * (“SIRVA ”); Special Processing Unit AND HUMAN SERVICES, * (“SPU”)

* Respondent. *

*

* * * * * * * * * * * * * * * * * * * * * * * * * * * * Brian L. Cinelli, Marcus & Cinelli, LLP, Williamsville, NY, for petitioner. Heather Pearlman, U.S. Department of Ju stice, Washington, DC, for respondent.

RULING ON ENTITLEMENT 1

Dorsey , Chief Special Master:

On May 27, 2015, Winifred Campbell fil ed a petition for co mpensation under the National Vaccine Injury Compensat ion Program, 42 U.S.C. §300aa-10, et seq.

, 2 [the “Vaccine Act” or “Progr am”]. Petitioner alleges that as a result of an influenza [“flu”] vaccination on October 23, 2013, she suffered adhesive capsulitis. Petition at 1. The case was assigned to the Special Processing Unit of the Office of Special Masters.

On September 9, 2015, respondent filed her Rule 4(c) report in which she concedes that petitioner is entitled to compen sation in this case. Respondent’s Rule 4(c) Report at 1, 4. Specifically, respondent indicate s that she “believes that petitioner’s alleged injury is consistent with a shoulde r injury related to vaccine administration (‘SIRVA’)” and that “petitioner met the statutory requirement s by suffering the condition
for more than six months.” Id. at 4.

1 Because this unpublished ruling contains a reasoned explanation for the action in this case, I intend to post it on the United States Court of Federal Claims' website, in accordance with the E-Government Act of 2002, Pub. L. No. 107-347, § 205, 116 Stat. 2899, 2913 (codified as amended at 44 U.S.C. § 3501 note (2006)). In accordance with Vaccine Rule 18(b), petitioner has 14 days to identify and move to redact medical or other information, the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that the identified mate rial fits within this definition, I will redact such material from public access.

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease of citation, all “§” references to the Vaccine Ac t will be to the pertinent subparagraph of 42 U.S.C. § 300aa (2012).2 In view of respondent’s concession a nd the evidence before me, I find that petitioner is entitled to compensation.

IT IS SO ORDERED. s/Nora Beth Dorsey Nora Beth Dorsey Chief Special Master
Adam Douglas BOYLEN, Petitioner, v. UNITED STATES.

No. 19-6311

Supreme Court of the United States.

Nov. 18, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
# C_2018315EN.01000102.xml

| 7.9.2018 | EN | Official Journal of the European Union | C 315/1 |
| --- | --- | --- | --- |

7.9.2018

EN

Official Journal of the European Union

C 315/1

---

Non-opposition to a notified concentration

(Case M.8862 — GBT/HRG)

(Text with EEA relevance)

(2018/C 315/02)

On 13 July 2018, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M8862. EUR-Lex is the online access to European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M8862. EUR-Lex is the online access to European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
xml version="1.0" encoding="UTF-8"?


C\_2018295EN.01000301.xml


| | | | |
| --- | --- | --- | --- |
| 21.8.2018 | EN | Official Journal of the European Union | C 295/3 |

---

Prior notification of a concentration

(Case M.8981 — IFF/Frutarom)

Candidate case for simplified procedure

(Text with EEA relevance)

(2018/C 295/03)

1.

On 10 August 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2018295EN.01000301-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | International Flavors & Fragrances Inc. (‘IFF’) (United States), |

| | |
| --- | --- |
| — | Frutarom Industries Ltd. (‘Frutarom’) (Israel). |

IFF acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Frutarom. The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

—   for IFF: developing, creating, and selling flavours and fragrances that are used in consumer goods industries, such as food and beverage, personal care, or household products industries,

—   for Frutarom: developing, producing, and marketing taste and health products, including flavours, fine ingredients, pharmaceutical/nutraceutical products, and cosmetics and personal care products that are used, amongst others, in the food and beverage, pharmaceutical, and cosmetics industries.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2018295EN.01000301-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.8981 — IFF/Frutarom

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| |
| --- |
| Email: COMP-MERGER-REGISTRY@ec.europa.eu |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2018295EN.01000301-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2018295EN.01000301-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---
352 U.S. 881, 77 S.Ct. 104.

#### James A. WILLIAMS, petitioner, v. John E. PETERS and Chester E. Strand.

No. 94, Misc.

Supreme Court of the United States.

Oct. 22, 1956.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit.

Denied.
Joseren Deshune DELANCY, Petitioner v. FLORIDA.

No. 19-6331

Supreme Court of the United States.

November 18, 2019

Petition for writ of certiorari to the District Court of Appeal of Florida, Fourth District denied.
Exhibit
32.1




CERTIFICATION




In
connection with the accompanying Quarterly Report on Form 10-Q of PROLOR
Biotech, Inc. for the period ended June 30, 2010 (the “Report”), the undersigned
hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and
belief, that:




(1)
            the
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and




(2)
            the
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of PROLOR
      Biotech, Inc.




/s/ Abraham HavronAbraham
      HavronChief
      Executive OfficerPROLOR
      Biotech, Inc.


August
13, 2010




The
certification set forth above is being furnished as an Exhibit solely pursuant
to Section 906 of the Sarbanes—Oxley Act of 2002 and is not being filed as part
of the Report or as a separate disclosure document of PROLOR Biotech, Inc. or
the certifying officers.
xml version="1.0" encoding="UTF-8"?


C\_2018267EN.01000401.xml


| | | | |
| --- | --- | --- | --- |
| 30.7.2018 | EN | Official Journal of the European Union | C 267/4 |

---

Prior notification of a concentration

(Case M.8992 — Maritime Holdings/Zeaborn/Zeamarine JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2018/C 267/04)

1.

On 20 July 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2018267EN.01000401-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | Maritime Holdings (Delaware), LLC (‘Maritime Holdings’, United States) controlled by New Mountain Capital (United States), |

| | |
| --- | --- |
| — | Zeaborn Chartering Management GmbH (‘Zeaborn’, Germany), |

| | |
| --- | --- |
| — | Zeamarine GmbH (‘Zeamarine JV’, Germany). |

Maritime Holdings and Zeaborn acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Zeamarine JV.

The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2.

The business activities of the undertakings concerned are:

—   for Maritime Holdings: ocean cargo shipping,

—   for Zeaborn: multipurpose cargo shipping services,

—   for Zeamarine JV: multipurpose cargo shipping (liner/semi-liner and tramp).

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2018267EN.01000401-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.8992 — Maritime Holdings/Zeaborn/Zeamarine JV

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| |
| --- |
| Email: COMP-MERGER-REGISTRY@ec.europa.eu |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2018267EN.01000401-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2018267EN.01000401-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---
EXHIBIT 32.b



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BCTC V Assignor Corp. (the "registrant") on Form 10-Q for the period ended March 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Marc N. Teal, Principal Financial Officer of the registrant, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge, after due inquiry:



|(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                  
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                        
|(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.



|             |  |                            
|------------ |  | ---------------------------
|Date:        |  |                            
|May 13, 2005 |  | /s/ Marc N. Teal           
|             |  |                            
|             |  | Marc N. Teal               
|             |  | Principal Financial Officer
|             |  |                            
|             |  |                            

A signed original of this written statement required by Section 906, or other

document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the registrant and will be retained by the registrant and furnished to the Securities and Exchange Commission or its staff upon request.
Frank SARCONA, Petitioner, v. UNITED STATES

No. 19-5012

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Fernando QUINTELA-GALINDO, Petitioner, v. UNITED STATES.

No. 19-6656

Supreme Court of the United States.

January 13, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER  REDDY ICE HOLDINGS, INC.  PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  (CHAPTER 98, TITLE 15 U.S.C. SS. 7241)

I,
Steven J. Janusek, certify that:

1.     I
have reviewed this quarterly report on Form 10-Q of Reddy Ice Holdings, Inc.;

2.     Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;

3.     Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the period presented in this report;

4.     The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:



5.     The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



Date:
April 22, 2010

/s/ STEVEN J. JANUSEK Steven J. Janusek,
Chief Financial Officer


---



QuickLinks
Exhibit 32.2





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Physicians Formula Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2009, as filed with the Securities and Exchange Commission (the “Report”), I, Jeff Berry, Interim Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:





(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





The foregoing certification is being furnished solely pursuant to 18 U.S.C. §1350 and is not being filed as part of the Report or as a separate disclosure document.





Date: November 9, 2009





By:
/s/ Jeff BerryName:
Jeff BerryTitle:
Interim Chief Financial Officer





A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906,
has been provided to Physicians Formula Holdings, Inc. and will be retained by Physicians Formula Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
SMITH BARNEY NEW JERSEY MUNICIPALS FUND INC. PRIVATE  


	ARTICLES OF AMENDMENT


Smith Barney New Jersey Municipals Fund Inc., a Maryland 
corporation, having its principal office in Baltimore City, 
Maryland (the "Corporation"), hereby certifies to the State 
Department of Assessments and Taxation of Maryland that:

FIRST:  The Charter of the Corporation is hereby amended to provide 
that the name of all of the issued and unissued Class C Common 
Stock of the Corporation is hereby changed to Class L Common Stock. 

SECOND:  The foregoing amendment to the Charter of the Corporation 
has been approved by a majority of the entire Board of Directors 
and is limited to a change expressly permitted by Section 2-605 of 
the Maryland General Corporation Law to be made without action of 
the stockholders.

THIRD:  The Corporation is registered as an open-end investment 
company under the Investment Company Act of 1940.

FOURTH:  The amendment to the Charter of the Corporation effected 
hereby shall become effective at 9:00 a.m. on June 12, 1998. 

IN WITNESS WHEREOF, Smith Barney New Jersey Municipals Fund Inc. 
has caused these presents to be signed in its name and on its 
behalf by its President and witnessed by its Assistant Secretary as 
of June 1, 1998.


WITNESS:					SMITH BARNEY NEW JERSEY 
MUNICIPALS FUND INC.


/s/ Michael Kocur   	 	By: /s/Heath B. McLendon       
          		 
Michael Kocur	 			       Heath B. McLendon
Assistant Secretary		       President
						



	

THE UNDERSIGNED, President of Smith Barney New Jersey Municipals 
Fund Inc., who executed on behalf of the Corporation Articles of 
Amendment of which this Certificate is made a part, hereby 
acknowledges in the name and on behalf of said Corporation the 
foregoing Articles of Amendment to be the corporate act of said 
Corporation and hereby certifies that the matters and facts set 
forth herein with respect to the authorization and approval thereof 
are true in all material respects under the penalties of perjury.


					 /s/Heath B. McLendon                  
         
					Heath B. McLendon, President








LEGAL\FUNDS\NJMU\NJMUAMND.DOC
_________________________________________ 

 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

October 24, 2007 Clifford W. Taylor,

 Chief Justice 

133383 & (48) Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

Maura D. Corrigan 

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee, 

Robert P. Young, Jr. 

Stephen J. Markman,

 Justices 

v SC: 133383 

 COA: 264991 

Eaton CC: 04-020431-FH 

CARRIE EVERETT COTTRELL,

Defendant-Appellant. 

_________________________________________/ 

By order of June 29, 2007, the prosecuting attorney was directed, and defendant 

was invited, to submit supplemental briefs addressing two specified issues raised by the 

application for leave to appeal the February 1, 2007 judgment of the Court of Appeals. 

On order of the Court, the supplemental briefs having been received, the application for 

leave to appeal is again considered, and it is DENIED, because we are not persuaded that 

the questions presented should be reviewed by this Court. 

KELLY, J., would grant leave to appeal. 

p1017 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

October 24, 2007 

 Clerk
Bobby Ray TURNER, Petitioner, v. TEXAS.

No. 18-9430

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the Court of Appeals of Texas, Sixth District denied.
Dante TAYLOR, Petitioner, v. NEW YORK.

No. 18-9485

Supreme Court of the United States.

November 4, 2019

Petition for writ of certiorari to the Appellate Division, Supreme Court of New York, Fourth Judicial Department denied.
Roderick WHITE, Petitioner v. LOUISIANA.

No. 18-8862

Supreme Court of the United States.

December 9, 2019

Motion of National Association of Criminal Defense Lawyers for leave to file a brief as *amicus curiae* granted. Petition for writ of certiorari to the Court of Appeal of Louisiana, First Circuit denied.
Exhibit 32.1




CERTIFICATION PURSUANT
TO


18 U.S.C.
SECTION 1350,


AS ADOPTED PURSUANT
TO


SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002




In
connection with the Quarterly Report of Physicians Formula Holdings, Inc.
(the “Company”) on Form 10-Q for the quarter ended March 31, 2009, as
filed with the Securities and Exchange Commission (the “Report”), I, Ingrid
Jackel, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
§1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002,
that:




(1)
      The Report fully complies with the requirements of
      Section 13(a) or 15(d) of the Securities Exchange Act of
      1934; and




(2)
      The information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.




The
foregoing certification is being furnished solely pursuant to 18 U.S.C. §1350
and is not being filed as part of the Report or as a separate disclosure
document.




Date:
May 11, 2009




By:
            /s/
      Ingrid JackelName:
            Ingrid
      JackelTitle:
            Chief
      Executive Officer







A signed
original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
required by Section 906, has been provided to Physicians Formula
Holdings, Inc. and will be retained by Physicians Formula
Holdings, Inc. and furnished to the Securities and Exchange Commission or
its staff upon request.